Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease?
© Flierl et al; licensee BioMed Central Ltd. 2011
Received: 12 January 2011
Accepted: 4 May 2011
Published: 4 May 2011
Anorexia nervosa carries the highest mortality rate of any psychiatric disorder. Even the most critically ill anorexic patients may present with normal 'standard' laboratory values, underscoring the need for a new sensitive biomarker. The complement cascade, a major component of innate immunity, represents a driving force in the pathophysiology of multiple inflammatory disorders. The role of complement in anorexia nervosa remains poorly understood. The present study was designed to evaluate the role of complement C3 levels, the extent of complement activation and of complement hemolytic activity in serum, as potential new biomarkers for the severity of anorexia nervosa.
Patients and methods
This was a prospective cohort study on 14 patients with severe anorexia nervosa, as defined by a body mass index (BMI) <14 kg/m2. Serum samples were obtained in a biweekly manner until hospital discharge. A total of 17 healthy subjects with normal BMI values served as controls. The serum levels of complement C3, C3a, C5a, sC5b-9, and of the 50% hemolytic complement activity (CH50) were quantified and correlated with the BMIs of patients and control subjects.
Serum C3 levels were significantly lower in patients with anorexia nervosa than in controls (median 3.7 (interquartile range (IQR) 2.5-4.9) vs 11.4 (IQR 8.9-13.7, P <0.001). In contrast, complement activation fragments and CH50 levels were not significantly different between the two groups. There was a strong correlation between index C3 levels and BMI (Spearman correlation coefficient = 0.71, P <0.001).
Complement C3 serum levels may represent a sensitive new biomarker for monitoring the severity of disease in anorexia nervosa. The finding from this preliminary pilot study will require further investigation in future prospective large-scale multicenter trials.
Anorexia nervosa occurs in an estimated 0.9% of women and 0.3% of men in the US alone . The treatment course is usually lengthy and challenging due to potentially life-threatening medical complications that can affect almost every organ system . Such impediments result in the highest death rates (approximately 5%) of any psychiatric disorder [2, 3]. In fact, the overall mortality rate in anorexia nervosa patients is about 10 times higher than the expected mortality for age-matched women in the US [2, 3]. Published guidelines support hospitalization for medical stabilization when patients with anorexia nervosa weigh less than 70% of their calculated ideal body weight (IBW), have severe bradycardia (≤50 beats/min), severe hypotension, or life threatening electrolyte abnormalities [2, 4, 5]. In this population of young, usually otherwise healthy patients with pure food restriction, normal serum albumin levels frequently mask the severity of their serious medical condition [6, 7]. A recent analysis of patients with severe anorexia nervosa (median body mass index 13.1 kg/m2) admitted for medical stabilization showed that most patients, despite profoundly low body weight, have normal laboratory values on admission, with the exception of lymphopenia and anemia due to starvation-mediated bone marrow suppression [2, 4]. However over the course of the early weeks of refeeding, nearly half developed hypoglycemia, three-quarters showed abnormal liver function most likely related to starvation-induced autophagy, 83% showed abnormal bone density, nearly half developed refeeding hypophosphatemia, and 92% were hypothermic [8, 9]. Despite the significant abnormalities and the extent of bone marrow suppression, these critically ill patients do not manifest significant inflammatory or infectious processes. Outcome measures of medical stability draw from a combination of factors including improvement of standard laboratory values, ingestion of adequate calories to begin weight restoration, and resolution of comorbidities [4, 10, 11]. To date, no appropriate biomarker exists to monitor treatment success or progression of disease [4, 12].
Complement represents one of the phylogenetically oldest cascade systems. As an important effector of the innate immune response, the complement system represents the 'first line of defense' against invading pathogens . Although of beneficial intention, excessive complement activation has been associated with detrimental effects related to 'innocent bystander' host cell injury . Disproportionate complement activation in sepsis, for example, appears to play a key role in the pathophysiology of neutrophil dysfunction, coagulopathy, apoptotic events and cardiomyopathy [15, 16]. There is relative paucity of data on the role of complement proteins in anorexia nervosa in the literature and no correlations were made between complement levels and the severity of disease. Moreover, anorexia nervosa has traditionally been viewed as an illness with malnourishment, but devoid of a prominent inflammatory component, as shown by surprisingly normal albumin levels [6, 7].
The present study was designed to assess complement activation in patients with severe anorexia nervosa, and to determine whether complement serum levels may represent a useful marker for determining and monitoring the severity of disease. We hypothesized that anorexia nervosa results in complement activation and consumption of complement C3, the central component of all complement activation pathways.
Patients and methods
The Acute Comprehensive Urgent Treatment of Eating disorders (ACUTE) center at Denver Health Medical Center is a five-bed, multidisciplinary center that cares for the largest number of critically ill anorexic patients in the country. It serves patients too medically compromised to initiate or continue treatment in a psychiatrically based eating disorder program. Therefore, the ACUTE center is a medical stabilization unit treating the most seriously ill anorexic patients. Although hospitalization is recommended for anorexic patients with a body mass index (BMI) under 14 kg/m2, the ACUTE center's patients have a mean BMI of 12.6 kg/m2, making them a uniquely ill patient population. It is worth noting that the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for anorexia nervosa defines this illness as having a BMI <17.5. Thus the patients in this study have extremely severe forms of anorexia nervosa. Upon primary medical stabilization, patients are transferred to a psychiatrically based inpatient eating disorder program further treatment and follow-up.
Patients and controls
The present study was designed as a prospective cohort study. Prior to study initiation, approval by the Institutional Review Board was obtained. Patients admitted to the ACUTE center with a diagnosis of severe anorexia nervosa were consented and enrolled into the study (n = 14). Blood samples were obtained every 2 weeks and demographic data, routine laboratory parameters (complete blood counts, electrolytes and minerals, hepatic function tests), and body weight were assessed in standard fashion until discharge. Patients provided blood samples only during their hospitalization so patients did not contribute the same number of samples to the study. A healthy volunteer group of 17 individuals served as the control group for this study and blood samples were obtained once.
Whole blood was sampled via venipuncture of the anticubital vein. Serum tubes were used in all cases, and were immediately put on ice. Serum was collected after clotting and centrifugation at 800 g for 10 min at 4°C. To avoid repeated freeze-thaw cycles, samples were aliquoted and stored at -80°C until further analysis.
The total protein content of serum samples was quantified using BCA protein measurement (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's instructions. Samples were diluted 1:100 in phosphate-buffered saline (PBS) prior to incubation and spectrophotometric assessment. Bovine serum albumin (Thermo Scientific) was used to generate a standard curve.
Complement hemolytic activity and serum levels
Serum samples were thawed and processed immediately. Repetitive freeze-thaw cycles were avoided to minimize in vitro complement activation. The following commercially available ELISA kits were used strictly according to the manufacturer's protocol: MicroVue CH50 Eq EIA kit (Quidel, San Diego, CA, USA; sample dilution per manufacturer's protocol); C3 fixed complement preceptor ELISA kit (Bachem, San Carlos, CA, USA; 1:20 sample dilution); MicroVue C3a EIA kit (Quidel; 1:150 sample dilution); human complement component C5a ELISA (R&D, Minneapolis, MN, USA; 1:20 sample dilution); MicroVue sC5b-9 EIA kit (Quidel). Obtained concentrations were protein adjusted (concentration/mg total protein) in order to address differences in total protein levels between anorexia nervosa patients and healthy volunteers.
Baseline characteristics of the study participants are described with mean and standard deviation (SD) or percentages. Complement levels are expressed as medians with interquartile ranges because they were non-normally distributed (Anderson-Darling test). Comparisons between the anorexia nervosa patients and healthy volunteers were analyzed with an unpaired t test, Wilcoxon rank sum test, or Fisher's exact test, as appropriate. Spearman correlation coefficients were used to determine association between BMI and complements. A generalized estimating equation (GEE) analysis was used to determine the relationship between BMI and complement level over time for the anorexia nervosa patients. PROC GENMOD was used since it accounts for the repeated measures within a patient, allows missing data, and does not require the response to be normally distributed. Differences were considered significant when P <0.05. All analyses were conducted in SAS v.9.1. (SAS, Cary, NC, USA).
Anorexia nervosa patients
30.4 ± 3.7
32.4 ± 12.8
66.4 ± 4.4
64.0 ± 3.2
Initial weight, pounds
140.6 ± 31.4
80.6 ± 11.6
Initial body mass index, kg/m2
22.2 ± 2.6
13.6 ± 1.5
Initial percentage of ideal body weight
104.1 ± 11.4
64.5 ± 7.6
Serum total protein, mg/ml
73.7 ± 9.6
61.9 ± 8.2
Admission albumin levels (normal: 3-5.3 g/dl)
3.6 ± 0.7
Length of follow-up, days
49.4 ± 31.7b
Peripheral blood cell count in patients with anorexia nervosa (n = 14).
Cell count (laboratory normal range)
Mean ± SD or median (IQR)
Neutrophils (48.0% to 69.0%)
56.2% ± 11.3%
37.9% to 77.5%
Absolute neutrophils (2.0-7.0 k/μl)
33.6% ± 10.9%
16.7% to 53.0%
Absolute lymphocytes (0.9-4.0 k/μl)
1.4 ± 0.5
Complement hemolytic activity and serum levels
Complement levels in anorexia patients and controls
Complement activation adjusted for protein
Anorexia nervosa patients
(admission laboratory test results)
Patient numbers, n
CH50, U Eq/ml
C3, ng/mg protein
C3a, ng/mg protein
C5a, pg/mg protein
sC5b-9, ng/mg protein
Increase in BMI correlates with complement activation
Serum samples were obtained from anorexia nervosa patients in a biweekly manner after initiation of refeeding and analyzed for levels of CH50, C3, C3a, C5a and sC5b-9. Each patient provided between one and six sets of laboratory results depending on the length of their hospitalization. Eight patients (57%) had multiple blood samples and were included in the longitudinal analysis. As the patients became medically stabilized during their admission, BMI increases over time were not statistically correlated with C3 changes.
This study provides first evidence of significantly decreased complement C3 levels in patients with severe anorexia nervosa, compared to healthy control subjects. There was a strong correlation between index C3 levels and patients' and controls' BMI values (Spearman correlation coefficient = 0.71, P <0.001), suggesting that serum C3 levels may represent a clinically relevant serum marker reflecting the severity of disease, and potentially serving as a guide for monitoring the refeeding process. That is, in patients with anorexia nervosa and severely low body weight, in whom basic laboratory tests are often normal, low serum C3 levels can confirm biochemical evidence of severe illness. It is reasonable that serum C3 levels did not correlate with BMI in the anorexia group alone, reflective of the fact that a 'threshold' of severe illness from anorexia has been crossed at these profoundly low body weights, which occasioned the low C3 level. The fact that serum C3 levels did not statistically correlate with weight restoration over the course of treatment may have a complex explanation, and thus restoration of non-edematous weight remains the best marker of physiologic recovery in anorexia nervosa. In contrast to the findings on C3 concentrations, serum levels of complement activation fragments (C3a, C5a, C5b-9) and the extent of complement hemolytic activity (CH50) did not significantly correlate with the patients' BMIs. There are several potential explanations for this negative finding. First, a recent study described direct cleavage of C5 via thrombin, thereby bypassing the traditional activation cascade using C3 convertases or C5 convertases . As a result, C5a may be generated via thrombin-mediated coagulation abnormalities that have been documented in anorexia nervosa patients [17, 18]. In addition, phacocytic cells are able to directly cleave C5 and locally generate C5a . Maj and colleagues revealed that peripheral mononuclear cells (PBMCs) isolated from anorexia nervosa patients exhibited significantly elevated levels of activated intracellular G proteins, indicating increased PBMC activity in these patients . Thus, activated PBMCs and neutrophils may further contribute to alterations of C3a and C5a levels bypassing the traditional complement activation cascade.
There are few reports on complement activation in anorexia nervosa available in the peer-reviewed literature, dating back to the 1970s and 1980s [21–23]. Wyatt et al. published a series of five anorexia nervosa patients and observed significantly decreased serum levels of C1q, C2, C3, factor B, β leutenizing hormone (β-LH), C3b inactivator, properdin, and C4 binding protein . After initiation of alimentation, β-LH, C3b inactivator, C3, and factor B rapidly returned to the normal range in response to therapy . In line with these findings, Sigal and colleagues found low serum levels of complement proteins in anorexia nervosa patients . A more recent report evaluated several components of the complement cascade and analyzed the activities of the alternative complement activation pathways . Serum levels of C3, Factor B and D, hemolytic activity of the alternative pathway, and the inhibitors H and I were found to be low in anorexia patients and normalized with weight gain . In our current study, we determined low C3 levels in anorexic patients, which is in line with those previous findings. However, while our findings suggest complement consumption secondary to increased activation in anorexic patients, Pomeroy and colleagues concluded that low serum complement levels were attributable to hypoproduction as opposed to increased consumption, and that percentage of ideal body weight, changes in body weight, and serum transferrin were each highly correlated with serum levels of complement proteins . These differences to our findings may be due to the fact that Pomeroy and colleagues assessed functional capacity of the alternative complement activation pathway exclusively, while our study focused on complement activation via the classical pathway (CH50) and complement activity further downstream (C3a, C5a, MAC). Moreover, Pomeroy et al. failed to adjust their samples to total protein levels, which may have resulted in variable protein concentrations. In the present study, anorexia nervosa patients had significantly lower serum total protein levels than healthy controls on admission (61.9 ± 2.2 mg/ml vs 73.7 ± 2.3 mg/ml; P = 0.003) . Nova and colleagues evaluated several biochemical markers in 14 anorexia nervosa patients and compared them to a healthy control cohort of (n = 15) . The authors reported significantly increased concentrations of C3 (and C4) upon admission in anorexia nervosa patients . At the 1-year follow-up, C3 and C4 levels had returned to levels comparable to the healthy control cohort. Nova et al. also failed to adjust their measurements to total protein levels in their samples, which may account for the differences observed.
Our study has several limitations. First, the low patient numbers limit the power of our statistical analysis and make our data vulnerable to a statistical type II error. Therefore, our data do not allow for advocating complement serum levels as a new biomarker until definitively proven in future large-scale prospective studies. Moreover, follow-up studies will have to determine during which time frame complement levels return to healthy control levels after initiation of refeeding protocols, and whether complement serum levels may represent a valuable tool to monitor therapy success or failure in anorexia patients. Nevertheless, to our knowledge, our study is the first to describe a full complement screening in severely ill anorexia nervosa patients upon admission, and to correlate complement levels with gain of body weight as a function of time.
The complement system represents a crucial effector of the acute phase response of innate immunity. Excessive complement activation, however, has been implicated in the pathophysiology of various inflammatory diseases [14, 16, 26]. Therefore, it is conceivable that the increased complement activation observed in anorexia nervosa patients may be involved in the development of complications associated with severe anorexia nervosa. The pharmacological complement blockade has been shown to ameliorate the severity of numerous diseases, including sepsis , neuroinflammation [14, 28], chest trauma , and ischemia reperfusion injury . Therefore, it appears reasonable to hypothesize that the pharmacological blockade of the complement cascade or complement receptors may represent a future therapeutic treatment strategy to reduce the incidence of anorexia nervosa-associated complications. In conclusion, future prospective large-scale studies will have to determine the value of complement serum levels as potential biomarkers to monitor treatment success or failure in patients with severe anorexia nervosa.
The authors are indebted to the nursing staff who performed the phlebotomies and to the patients and healthy volunteers enrolled into this study.
- Hudson JI, Hiripi E, Pope HG, Kessler RC: The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007, 61: 348-358. 10.1016/j.biopsych.2006.03.040.PubMed CentralView ArticlePubMedGoogle Scholar
- Mehler PS, Krantz M: Anorexia nervosa medical issues. J Womens Health. 2003, 12: 331-340. 10.1089/154099903765448844.View ArticleGoogle Scholar
- Steinhausen HC: The outcome of anorexia nervosa in the 20th century. Am J Psychiatry. 2002, 159: 1284-1293. 10.1176/appi.ajp.159.8.1284.View ArticlePubMedGoogle Scholar
- Mehler PS, Winkleman AB, Andersen DM, Gaudiani JL: Nutritional rehabilitation: practical guidelines for refeeding the anorectic patient. J Nutr Metab. 2010, pii: 625782-Google Scholar
- Schwartz BI, Mansbach JM, Marion JG, Katzman DK, Forman SF: Variations in admission practices for adolescents with anorexia nervosa: a North American sample. J Adolesc Health. 2008, 43: 425-431. 10.1016/j.jadohealth.2008.04.010.View ArticlePubMedGoogle Scholar
- Krantz MJ, Lee D, Donahoo WT, Mehler PS: The paradox of normal serum albumin in anorexia nervosa: a case report. Int J Eat Disord. 2005, 37: 278-280. 10.1002/eat.20129.View ArticlePubMedGoogle Scholar
- Narayanan V, Gaudiani JL, Mehler PS: Serum albumin levels may not correlate with weight status in severe anorexia nervosa. Eat Disord. 2009, 17: 322-326. 10.1080/10640260902991202.View ArticlePubMedGoogle Scholar
- Gaudiani J, Sabel AL, Mascolo M, Mehler PS: Severe anorexia nervosa: Outcomes from a medical stabilization unit. Int J Eat Disord.Google Scholar
- Mehler PS, Weiner KL: Use of total parenteral nutrition in the refeeding of selected patients with severe anorexia nervosa. Int J Eat Disord. 2007, 40: 285-287. 10.1002/eat.20371.View ArticlePubMedGoogle Scholar
- Narayanan V, Gaudiani J, Harris RH, Mehler PS: Liver function test abnormalities in anorexia nervosa - cause or effect. Int J Eat Disord. 2010, 43: 378-381.PubMedGoogle Scholar
- Mehler PS, MacKenzie TD: Treatment of osteopenia and osteoporosis in anrexia nervosa: a systematic review of the literature. Int J Eat Disord. 2009, 42: 195-201. 10.1002/eat.20593.View ArticlePubMedGoogle Scholar
- Prince AC, Brooks SJ, Stahl D, Treasure J: Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders. Am J Clin Nutr. 2009, 89: 755-765. 10.3945/ajcn.2008.27056.View ArticlePubMedGoogle Scholar
- Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006, 12: 682-687. 10.1038/nm1419.View ArticlePubMedGoogle Scholar
- Stahel PF, Barnum SR: The role of the complement system in CNS inflammatory diseases. Expert Rev Clin Immunol. 2006, 2: 445-456. 10.1586/1744666X.2.3.445.View ArticlePubMedGoogle Scholar
- Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008, 8: 776-787. 10.1038/nri2402.PubMed CentralView ArticlePubMedGoogle Scholar
- Schreiber H, Rittirsch D, Flierl M, Brueckner U, Schneider M, Weiss M, Gebhard F, Huber-Lang M: Complement activation during sepsis in humans. Adv Exp Med Biol. 2006, 586: 217-226. 10.1007/0-387-34134-X_15.View ArticlePubMedGoogle Scholar
- Gaudiani JL, Kashuk JL, Chu ES, Narayanan V, Mehler PS: The use of thrombelastography to determine coagulation status in severe anorexia nervosa: a case series. Int J Eat Disord. 2010, 43: 382-385.PubMedGoogle Scholar
- Cleary BS, Gaudiani JL, Mehler PS: Interpreting the complete blood count in anorexia nervosa. Eat Disord. 2010, 18: 132-139. 10.1080/10640260903585540.View ArticlePubMedGoogle Scholar
- Huber-Lang M, Younkin EM, Sarma JV, Riedemann N, McGuire SR, Lu KT, Kunkel R, Younger JG, Zetoune FS, Ward PA: Generation of C5a by phagocytic cells. Am J Pathol. 2002, 161: 1849-1859. 10.1016/S0002-9440(10)64461-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Monteleone P, Di Lieto A, Martiadis V, Pannuto M, Maj M: Altered immunoreactive levels of G proteins in peripheral mononuclear cells of patients with anorexia nervosa and bulimia nervosa. Mol Psychiatry. 2003, 8: 680-684. 10.1038/sj.mp.4001304.View ArticlePubMedGoogle Scholar
- Palmblad J, Fohlin L, Norberg R: Plasma levels of complement factors 3 and 4, orosomucoid and opsonic functions in anorexia nervosa. Acta Paediatr Scand. 1979, 68: 617-618. 10.1111/j.1651-2227.1979.tb05067.x.View ArticlePubMedGoogle Scholar
- Wyatt RJ, Farrell M, Berry PL, Forristal J, Maloney MJ, West CD: Reduced alternative complement pathway control protein levels in anorexia nervosa: response to parenteral alimentation. Am J Clin Nutr. 1982, 35: 973-980.PubMedGoogle Scholar
- Sigal LH, Snyder BK: Low serum complement levels in anorexia nervosa. Am J Dis Child. 1989, 143: 1391-1392.PubMedGoogle Scholar
- Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP: Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol. 1997, 108: 507-515. 10.1046/j.1365-2249.1997.3921287.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Nova E, Lopez-Vidriero I, Varela P, Toro O, Casas JJ, Marcos AA: Indicators of nutritional status in restricting-type anorexia nervosa patients: a 1-year follow-up study. Clin Nutr. 2004, 23: 1353-1359.View ArticlePubMedGoogle Scholar
- Flierl MA, Stahel PF, Rittirsch D, Huber-Lang M, Niederbichler AD, Hoesel LM, Touban BM, Morgan SJ, Smith WR, Ward PA, Ipaktchi K: Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit Care. 2009, 13: R12-10.1186/cc7710.PubMed CentralView ArticlePubMedGoogle Scholar
- Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, Schmal H, Friedl HP, Ward PA: Protective effects of C5a blockade in sepsis. Nat Med. 1999, 5: 788-792. 10.1038/10512.View ArticlePubMedGoogle Scholar
- Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha ME, Scheffler A, John T, Smith WR, Holers VM, Stahel PF: Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol. 2006, 199: 454-464. 10.1016/j.expneurol.2006.01.033.View ArticlePubMedGoogle Scholar
- Flierl MA, Perl M, Rittirsch D, Bartl C, Schreiber H, Fleig V, Schlaf G, Liener U, Brueckner UB, Gebhard F, Huber-Lang MS: The role of C5a in the innate immune response after experimental blunt chest trauma. Shock. 2008, 29: 25-31.PubMedGoogle Scholar
- Riedemann NC, Ward PA: Complement in ischemia reperfusion injury. Am J Pathol. 2003, 162: 363-367. 10.1016/S0002-9440(10)63830-8.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.